The Relevance Between the Level of Fetal Hemoglobin and Short-term Complications in Extremely Preterm Infants

Fetal Hemoglobin Clinical Trial

Official title:

The Relevance Between the Level of Fetal Hemoglobin and Short-term Complications in Extremely Preterm Infants

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05788562
• Other study ID #: wu hui
• Status: Not yet recruiting
• Start date: April 1, 2023
• Est. completion date: May 30, 2024

Study information

• Verified date: June 2022
• Source: The First Hospital of Jilin University
• Contact: Qu Yangming
• Phone: 15844092520
• Email: quym[@]jlu.edu.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A monocentric prospective study was conducted to find the relevance between the level of fetal hemoglobin and short-term complications in extremely preterm infants

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 92
• Est. completion date: May 30, 2024
• Est. primary completion date: February 18, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Day to 2 Months

Eligibility

Inclusion Criteria:

1. Preterm infants with gestational age <32 weeks or birth weight <1500g

2. Parents agree to attend

Exclusion Criteria:

1. serious functional or organic diseases

2. severe congenital deformity

3. parents reject to attend

Related Conditions & MeSH terms

• Fetal Hemoglobin

Locations

Country	Name	City	State
China	First hospital of Jilin University	Chang chun	Jilin

Sponsors (1)

Lead Sponsor	Collaborator
The First Hospital of Jilin University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence and severity of early complications in premature infants	include necrotizing enterocolitis,bronchopulmonary dysplasia,retinopathy, Intraventricular hemorrhage above degree ?,leukomalacia,late-onset sepsis	2022.1-2023.1